Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Celltech Group, UCB Pharma deal

CCH's board recommended an acquisition offer from UCB that would value CCH at £1.5 billion ($2.6 billion). CCH shareholders would

Read the full 205 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE